Addex Therapeutics Ltd. (fka ADDXF)

[tykundegex]

Article about PD-related diskinesia and mGluR5 from the MJFF:

https://www.michaeljfox.org/foundation/publication-detail.html?id=247

Taken from the article:

Reasons for optimism: In March of 2012, MJFF awardee Addex Therapeutics of Geneva, Switzerland announced positive Phase 2 clinical trial results for their mGluR5-targeting compound. The Addex medicine is aimed at treating both aspects of dyskinesia, which comprises jerky movements known as chorea and slow, sometimes painful, writhing movements known as dystonia. To date, the company's compound is the only experimental drug to have shown an impact on both aspects in pre-clinical testing. The Addex drug would also be only the second dyskinesia-targeted therapy to make it into the third phase of clinical testing, essentially the last round before a drug would look to be approved by the FDA...